Page 1079 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

candidemia in nonneutropenic patients. Ann Pharmacother. 45. Simpson C, Blitz S, Shafran SD. The effect of current manage-
2007;41:568-573. ment on morbidity and mortality in hospitalised adults with
27. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and funguria. J Infect. 2004;49:248-252.
outcomes of candidemia in 2019 patients: data from the pro- 46. Meersseman W, Lagrou K, Spriet I, et al. Significance of the
spective antifungal therapy alliance registry. Clin Infect Dis. isolation of Candida species from airway samples in critically
2009;48:1695-1703. ill patients: a prospective, autopsy study. Intensive Care Med.
28. Chow JK, Golan Y, Ruthazer R, et al. Factors associated with 2009;35:1526-1531.
candidemia caused by non-albicans Candida species versus 47. Delisle M-S, Williamson DR, Perreault MM, et al. The clinical
Candida albicans in the intensive care unit. Clin Infect Dis. significance of Candida colonization of respiratory tract secre-
2008;46:1206-1213. tions in critically ill patients. J Crit Care. 2008;23:11-17.
29. Malani A, Hmoud J, Chiu L, et al. Candida glabrata funge- 48. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality,
mia: experience in a tertiary care center. Clin Infect Dis. hospital stay, and cost due to candidemia: a case-control study
2005;41:975-981. using data from population-based candidemia surveillance.
30. Ruan SY, Lee LN, Jerng JS, et al. Candida glabrata fungaemia in Infect Control Hosp Epidemiol. 2005;26:540-547.
intensive care units. Clin Microbiol Infect. 2008;14:136-140. 49. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mor-
31. Luzzati R, Allegranzi B, Antozzi L, et al. Secular trends in noso- tality of nosocomial candidemia, revisited. Clin Infect Dis.
comial candidaemia in non-neutropenic patients in an Italian 2003;37:1172-1177.
tertiary hospital. Clin Microbiol Infect. 2005;11:908-913. 50. Blot SI, Vandewoude KH, Hoste EA, Poelaert J, Colardyn F.
32. Colombo AL, Nucci M, Park BJ, et al. Epidemiology of candi- Effects of nosocomial candidemia on outcomes of critically ill
demia in Brazil: a nationwide sentinel surveillance of candidemia patients. Am J Med. 2002;113:480-485.
in eleven medical centers. J Clin Microbiol. 2006;44:2816-2823. 51. Colombo AL, Guimaraes T, Silva LRBF, et al. Prospective obser-
vational study of candidemia in Sao Paulo, Brazil: incidence
33. Hachem R, Hanna H, Kontoyiannis D, et al. The changing
epidemiology of invasive candidiasis: Candida glabrata and rate, epidemiology, and predictors of mortality. Infect Control
Candida krusei as the leading causes of candidemia in hemato- Hosp Epidemiol. 2007;28:570-576.
logic malignancy. Cancer. 2008;112:2493-2499. 52. Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, man-
agement, and risk factors for death of invasive Candida infec-
34. Riddell J, Kauffman CA. The evolution of resistant Candida
species in cancer centers: implications for treatment and pro- tions in critical care: a multicenter, prospective, observational
phylaxis. Cancer. 2008;112:2334-2337. study in France (2005-2006). Crit Care Med. 2009;37:1612-1618.
53. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treat-
35. Vazquez JA, Sobel JD. Candidiasis. In: Kauffman CA, Pappas
PG, Sobel JD, Dismukes WE. eds. Essentials of Clinical Mycology, ment of Candida bloodstream infection until positive blood
2nd ed. New York NY: Springer; 2011:167-206. culture results are obtained: a potential risk factor for hospital
mortality. Antimicrob Agents Chemother. 2005;49:3640-3645.
36. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R.
Candida colonization and subsequent infections in critically ill 54. Garey KW, Rege M, Pai MP, et al. Time to initiation of flucon-
surgical patients. Ann Surg. 1994;220:751-758. azole therapy impacts mortality in patients with candidemia: a
multi-institutional study. Clin Infect Dis. 2006;43:25-31.
37. Borzotta AP, Beardsley K. Candida infections in critically ill
trauma patients: a retrospective case-control study. Arch Surg. 55. Klevay MJ, Ernst EJ, Hollanbaugh JL, et al. Therapy and out-
1999;134:657-664. come of Candida glabrata versus Candida albicans bloodstream
infection. Diagn Microbiol Infect Dis. 2008;60:273-277.
38. Playford EG, Marriott D, Nguyen Q, et al. Candidemia in non- 56. Munoz P, Bernaldo de Quiros JC, Berenguer J, et al. Impact of
neutropenic critically ill patients: risk factors for non-albicans the BACTEC NR system in detecting Candida fungemia. J Clin
Candida spp. Crit Care Med. 2008;36:2034-2039.
Microbiol. 1990;28:639-641.
39. Kontoyiannis DP, Vaziri I, Hanna HA, et al. Risk factors for 57. Wilson ML, Davis TE, Mirrett S, et al. Controlled comparison
Candida tropicalis fungemia in patients with cancer. Clin Infect of the BACTEC high-blood-volume fungal medium, BACTEC
Dis. 2001;33:1676-1681.
Plus 26 aerobic blood culture bottle, and 10-milliliter isolator
40. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. blood culture system for detection of fungemia and bacteremia.
Clinical significance of Candida isolated from peritoneum in J Clin Microbiol. 1993;31:865-871.
surgical patients. Lancet. 1989;2:1437-1440.
58. Gherna M, Merz WG. Identification of Candida albicans
41. Hoerauf A, Hammer S, Müller-Myhsok B, Rupprecht H. Intra- and Candida glabrata within 1.5 hours directly from positive
abdominal Candida infection during acute necrotizing pan- blood culture bottles with a shortened peptide nucleic acid
creatitis has a high prevalence and is associated with increased fluorescence in situ hybridization protocol. J Clin Microbiol.
mortality. Crit Care Med. 1998;26:2010-2015. 2009;47:247-248.
42. Sobel JD, Fisher JF, Kauffman CA, Newman CA. Candida 59. Shepard JR, Addison RM, Alexander BD, et al. Multicenter eval-
urinary tract infections: epidemiology. Clin Infect Dis. 2011;52: uation of the Candida albicans/Candida glabrata peptide nucleic
(in press) acid fluorescent in situ hybridization method for simultaneous
43. Kauffman CA, Vasquez JA, Sobel JD, et al. Prospective multi- dual-color identification of C. albicans and C. glabrata directly
center surveillance study of funguria in hospitalized patients. from blood culture bottles. J Clin Microbiol. 2008;46:50-55.
Clin Infect Dis. 2000;30:14-18. 60. Obayashi T, Yoshida M, Mori T, et al. Plasma (1→3)-beta-D-
44. Kauffman CA, Fisher JF, Sobel JD, Newman CA. Candida glucan measurement in diagnosis of invasive deep mycosis and
urinary tract infections: Diagnosis. Clin Infect Dis. 2011; fungal febrile episodes. Lancet. 1995;345:17-20.
52(suppl 6):S452-S456.

Section05-O-ref.indd 2 1/20/2015 4:51:22 PM